A phase II study to evaluate the efficacy and safety of BB-1701 in advanced or metastatic NSCLC patients with HER2 mutation/amplification

BB-1701 - BlissBio, Eisai

Halaven (eribulin mesylate) - Eisai

C. Zhou1; X. Li2; Q. Yu3; R. Ning4; M. Sun5; Q. Wang6; A. Liu7; H. Tang8; X. Tian8; Y. Zhou9; Z. Wei9

Jul 19, 2024